Sponsored By

Interview with the Innovators

Fostering Shared Treatment Decision-Making

Interview with the Innovators
Antibody Drug Conjugate Therapy for the Treatment of HER2+ and HER2-Low mBC

In this second installment, our expert panel suggests approaches to empowering patients to become involved in shared decision-making.

Video Library
Tajuana Bradley, MS, FNP-BC
Nurse Practitioner
Georgia Cancer Specialists
Northside Hospital Cancer Institute
Lawrenceville, GA
Ryan Haumschild, PharmD, MS, MBA, CPEL
Vice President, Ambulatory Pharmacy
Emory Healthcare
Atlanta, GA
Abbey J. Kaler, MS, APRN, FNP-C
University of Texas MD Anderson Cancer Center
Houston, TX
Susie Ulloa, RN, OCN, ONN-CG
Oncology Nurse Navigator
APT. Inc.
Gainesville, FL

Featuring:

Interview with the Innovators Presents:
Antibody Drug Conjugate Therapy for the Treatment of HER2+ and HER2-Low mBC

As the breast cancer landscape continues to evolve with new research, it is imperative for advance practice providers and nurse navigators to have a comprehensive understanding of the disease state and side effect management. This educational series is intended to enhance the knowledge of advanced practice providers and navigators around a treatment option now available to a new patient population with mBC. The publishers of JONS and JHOP are pleased to present this 6-part video series featuring expert commentary:

Related Items

Improving Abemaciclib Tolerability: Insights From the TRADE Dose-Escalation Study
By Jamie Carroll, APRN, CNP, MSN
Interview with the Innovators
Video Library
In this sixth installment, Ms Carroll discusses the TRADE study with abemaciclib and emphasizes the importance of individualized patient care, clear communication about dosing goals, and teamwork among healthcare providers to implement dose escalation effectively. This strategy aims to address patient concerns about side effects while ensuring adherence to the full treatment plan.
Managing Abemaciclib Side Effects: Practical Tips for Improving Patient Care
By Jamie Carroll, APRN, CNP, MSN
Interview with the Innovators
Video Library
In this fifth installment, Ms Carroll discusses strategies for managing adverse events associated with abemaciclib, emphasizing the importance of patient involvement and personalized care. She underscores the value of maintaining open communication and regular touchpoints with patients to address concerns, build trust, and ensure adherence to therapy. These strategies aim to improve the quality of life for patients on abemaciclib.
Managing Abemaciclib Toxicity: Proactive Strategies for Improved Patient Outcomes
By Heather Moore, PharmD, BCOP, CPP
Interview with the Innovators
Video Library
In this fourth installment, Dr Moore shares strategies for optimizing abemaciclib treatment through dose escalation and proactive toxicity management. She emphasizes patient education on managing common side effects and highlights the importance of ongoing patient engagement through touchpoints and clear communication to ensure successful treatment outcomes.
Journal of Oncology Navigation & Survivorship

Connect with Us

 
 

Contact Us | Editorial Board

Amplity

© Amplity, Inc. All rights reserved.

JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country

Back to Top

Amplity © Amplity, Inc. All rights reserved.

We Value Your Feedback! Tell Us How You Consume Content

Your feedback will help us tailor our content to better meet your needs and preferences.

*First Name
*Last Name
*Email
*What's your favorite format for experiencing our content?